VDPHL01 Explained: The Extended-Release Oral Minoxidil in Phase 3

Veradermics' extended-release oral minoxidil tablet met both co-primary endpoints in its first Phase 2/3 male trial (Study '302') with a clean cardiac safety profile. If confirmed in the second Phase 3 study — topline expected 2H 2026 — VDPHL01 would be the first FDA-approved oral hair-loss medication in nearly 30 years.

VDPHL01 is Veradermics, Incorporated's investigational extended-release oral minoxidil tablet, currently in late Phase 3 development for pattern hair loss in both men and women. The reason it matters: minoxidil is an established, well-understood, generic-cheap molecule that has been used off-label as low-dose oral minoxidil (LDOM) for the last decade with meaningful efficacy. VDPHL01 doesn't change the molecule — it changes the delivery. A proprietary extended-release gel-matrix formulation designed to eliminate the peak plasma concentrations that drive minoxidil's cardiac side effects, while extending the time above the minimum threshold needed for hair growth. If it holds up in the pivotal program, it would be the first FDA-approved oral hair-loss medication in nearly three decades — and the first ever FDA-approved oral minoxidil formulation specifically for hair loss.

The Phase 2/3 '302' data — what was actually reported

Veradermics announced positive topline results from Study '302' in April 2026, presented in more detail at the 2026 World Congress for Hair Research on May 30. Trial design and headline results:

• Enrollment: 519 adult men with mild-to-moderate androgenetic alopecia.
• Design: Randomized, double-blind, placebo-controlled, three-arm.
• Arms: VDPHL01 8.5 mg once daily; VDPHL01 8.5 mg twice daily; placebo.
• Primary endpoints: Non-vellus Target Area Hair Count (TAHC) and patient-reported improvement on the Androgenetic Alopecia Impact Rating Scale (AAIRS) at month 6. Both endpoints met with statistical significance.

Patient-reported outcomes on the AAIRS at 6 months:

• Any improvement reported: Placebo 35.6% · VDPHL01 QD 79.3% · VDPHL01 BID 86.0%
• "Improved" or "much improved": Placebo 13.4% · VDPHL01 QD 48.4% · VDPHL01 BID 62.9%

Both objective (hair count) and subjective (patient-reported) endpoints tracked together, which is one of the stronger signals a hair-loss drug can produce in a Phase 3 trial. Many candidates show objective density gains that don't translate to patient-perceived improvement, or vice versa. VDPHL01 delivered both.

The safety story — the reason ER matters

Immediate-release oral minoxidil has well-documented cardiac considerations: tachycardia, fluid retention, and rare but serious pericardial effects at higher doses. Low-dose oral minoxidil (LDOM), as prescribed off-label today at 0.25–5 mg daily, largely avoids these effects — but requires cardiovascular screening before starting and monitoring after. The pharmacokinetic behavior of immediate-release minoxidil produces sharp peak plasma concentrations shortly after dosing, then rapid drop-off; the cardiac effects that occur are associated with those peaks.

VDPHL01's extended-release gel matrix is designed to blunt those peaks while extending the time the drug remains above the minimum concentration threshold for hair growth (which is thought to depend on SULT1A1-mediated conversion to the active metabolite minoxidil sulfate). In Study '302':

• Treatment-emergent adverse event rates were similar between VDPHL01 and placebo.
• Discontinuation rates were lower on VDPHL01 than placebo.
• No treatment-related serious adverse events reported.
• No adverse events of special interest of cardiac origin reported.

This is a meaningfully cleaner safety profile than what you'd expect from immediate-release oral minoxidil at equivalent daily doses — which is the entire point of the extended-release approach.

Where VDPHL01 sits in 2026 — and when it might reach patients

• Study '302' (male Phase 2/3, 519 patients): Positive topline reported April 2026, presented in detail May 2026.
• Study '304' (second Phase 3 in males, ~500 patients): Enrollment completed February 2026, topline expected 2H 2026.
• Study '207' (female Phase 2, open-label): Positive topline announced July 2026.
• Study '306' (female Phase 2/3): Actively recruiting, topline anticipated 1H 2027.
• FDA filing: Not publicly guided as of publication, but the combined Phase 3 male program plus female pivotal data will be needed. Realistic earliest filing 2027, with FDA review typically taking 10–12 months for reformulations of established molecules.
• Commercial availability: Realistic earliest 2028, subject to trial outcomes and regulatory pace.

What this means for patients today

You're currently on off-label LDOM and it's working

No urgent action needed. Continue your current regimen with your prescriber. When VDPHL01 becomes available, the switch is a conversation to have then — the extended-release profile may offer slightly cleaner cardiovascular tolerability at equivalent efficacy, but if you're stable and tolerating LDOM well, there's no compelling reason to change ahead of approval.

You've been cautious about starting oral minoxidil

The extended-release profile of VDPHL01 addresses the primary cardiovascular concern that has kept some patients (and some prescribers) away from oral minoxidil. If FDA-approved on the current timeline, VDPHL01 may broaden the pool of appropriate candidates — particularly patients with borderline cardiovascular status where the peak-avoiding pharmacokinetics matter most. Worth tracking.

You're female and have been under-served by hair loss medicine

VDPHL01 is one of two pipeline drugs (with clascoterone) that could meaningfully expand female hair-loss options in 2027–2028. Female pattern hair loss patients — who have been largely locked out of 5-ARI use during reproductive years — would gain an FDA-approved oral option specifically studied in women. See our women's hair transplant article for the current female options landscape.

You're considering a hair transplant

The medication maintenance conversation post-transplant is the same regardless of whether your minoxidil is LDOM off-label or eventually branded VDPHL01. What matters is having a maintenance plan that protects your native hair from continued miniaturization. See our medication-and-transplant article for the framework.

What VDPHL01 is not, as of publication

How to actually follow or participate in trials

Veradermics is running trial enrollment through phlstudy.com (male) and phlstudy.com/female (female). If you're interested in trial participation, that's the legitimate route to potential VDPHL01 exposure. Understand that trial windows are narrow, exclusions can be strict, and randomization means placebo-arm exposure is possible.

Practical bottom line

VDPHL01 is the most advanced hair-loss drug in the pipeline in terms of both regulatory readiness and evidence base. The Study '302' data is strong on both objective and patient-reported measures, and the cardiac safety profile is exactly what the extended-release approach was designed to deliver. If Study '304' confirms the results in 2H 2026 and the female Phase 2/3 replicates in 1H 2027, FDA approval is a realistic base case for 2028. For patients currently on off-label LDOM, or thinking about starting oral minoxidil but hesitant about the cardiovascular profile, VDPHL01 is the drug worth tracking.

Frequently asked questions

Is VDPHL01 approved?

Not yet. VDPHL01 is investigational, in late Phase 3 development. Study '302' (male Phase 2/3, 519 patients) posted positive topline April 2026. Study '304' (second Phase 3 in males, ~500 patients) topline is expected in 2H 2026. Female Phase 2/3 Study '306' topline is anticipated 1H 2027. FDA filing would follow completion of the pivotal program. Realistic earliest commercial availability is 2028.

How is VDPHL01 different from regular oral minoxidil?

Same active molecule (minoxidil), different delivery. VDPHL01 is a proprietary extended-release gel-matrix tablet designed to blunt the peak plasma concentrations that drive minoxidil's cardiac side effects, while extending the time above the minimum concentration threshold needed for hair growth. Immediate-release oral minoxidil (available generically at 2.5 and 10 mg) produces sharper peak concentrations that are associated with the tachycardia and cardiac effects that historically limited its use for hair loss.

Can I get VDPHL01 now?

No. It's not commercially available anywhere in the world. The only legitimate way to access it currently is through Veradermics' ongoing clinical trials. Any pharmacy or clinic offering 'VDPHL01' today is either misusing the name or selling a compounded product that is not the same formulation as what Veradermics tested — the extended-release technology is proprietary and cannot be legally replicated by compounding pharmacies.

Should I wait for VDPHL01 or start LDOM now?

For most patients with actively progressing pattern hair loss, waiting 18–24 months for a potential approval is not the right trade-off. Every month of continued miniaturization costs you follicles that no future drug can bring back. Starting off-label low-dose oral minoxidil (LDOM) now, with your dermatologist, protects hair while you wait. Switching to VDPHL01 once approved is a straightforward conversation. See our LDOM article for what starting looks like.

Will VDPHL01 work for women?

The female program (Study '207' Phase 2 and Study '306' Phase 2/3) is actively enrolling and data should read out in 2026–2027. Study '207' open-label Phase 2 topline in July 2026 was positive. If the pivotal '306' study confirms in 1H 2027 and FDA approves for female pattern hair loss, VDPHL01 would be the first FDA-approved oral treatment for female pattern hair loss — a significant addition for a patient population that has been under-served by hair loss medicine.

Will VDPHL01 replace finasteride?

Almost certainly not, if approved. VDPHL01 (oral minoxidil ER) and finasteride work on completely different mechanisms — minoxidil extends anagen and improves follicle caliber; finasteride blocks DHT. They're complementary rather than competing, and the most effective regimens generally use both. VDPHL01 would likely replace immediate-release oral minoxidil and off-label LDOM as the standard oral minoxidil option, but it would sit alongside finasteride (or dutasteride, or clascoterone if approved) in a combination protocol.